Patients in England with ultra-rare kidney disease nephropathic cystinosis will soon be able to access a therapy that has ...

There's a change at the helm of Johnson & Johnson's pharma division in the offing, as executive vice president Jennifer ...

Sentiment towards Novo Nordisk was also hit by the acknowledgement that it has decided to abandon the development of ...

The only smudge in the financial picture was Lilly's recently launched oral GLP-1 agonist Foundayo (orforglipron), which brought in $98 million – below forecasts – and continues to be outsold by Novo ...

What does FDA's proposed DTC advertising rule mean for pharm... Last month, the FDA quietly added a proposed rule to the 2026 ...

Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus (BDBV), now causing the worst-ever outbreak of the disease in the Democratic Republic of the Congo (DRC).

Pathos AI has added to its pipeline of cancer drugs by licensing a bispecific antibody-drug conjugate (ADC) for solid tumours ...

News of the expanded cost-reduction drive came as Pfizer recorded 1% sales growth to $15 billion, driven by continued strong ...

A one-time $5.7 billion charge related to the just-completed $6.7 billion takeover of Terns Pharma and its oral BCR-ABL ...

The criteria developed by UK health technology assessment (HTA) agency NICE to decide who should be referred by GPs for ...

Under the terms of the deal, ‌Lantheus' shareholders will get $102.50 per share in cash when the deal closes, along with the ...

The last mega-mergers between big pharma companies were BMS' $74 billion deal with Celgene in 2019 and the $63 billion AbbVie ...